Please login to the form below

Not currently logged in
Email:
Password:

Combination therapies

This page shows the latest Combination therapies news and features for those working in and with pharma, biotech and healthcare.

Roche’s Tecentriq yields positive data in early stage NSCLC

Roche’s Tecentriq yields positive data in early stage NSCLC

In addition to its SCLC approval, Tecentriq is also approved in four NSCLC indications, as either a single agent or in combination with targeted therapies and chemotherapies. ... In January, Roche also received a breakthrough therapy designation (BTD)

Latest news

More from news
Approximately 0 fully matching, plus 104 partially matching documents found.

Latest Intelligence

  • A snapshot of… Enterprise Therapeutics A snapshot of… Enterprise Therapeutics

    The company envisages that its drugs will be effective as monotherapies and in combination with other CF therapies including CFTR modulators. ... We are fortunate that Enterprise is well positioned and funded by a combination of private investors and the

  • Detecting Alzheimer’s ahead of a cure Detecting Alzheimer’s ahead of a cure

    Many are now coming to the same conclusion: that a combination of different therapies and detection methods could be the answer to fighting Alzheimer’s. ... Alzheimer’s Research UK is launching head first into the fight, with a new drive towards

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    disease. Targeting tau. Tau is among the beneficiaries of the broader focus and emerging interest in combination therapies. ... These mechanisms may be complementary. “We think combination therapies between. antibodies and small molecules make a lot of

  • Combining therapies and combining research Combining therapies and combining research

    create new super-resistant combination therapies. ... This crucial observation was followed by combination therapies for other major disease areas such as AIDS and cancer.

  • Combined immunotherapies – potential and pitfalls Combined immunotherapies – potential and pitfalls

    Efforts to prevent resistance are also driving interest in combination therapies, said Matthew Galsky, MD, professor of medicine, haematology and medical oncology, Mount Sinai Hospital in New York. ... The risk of autoimmune responses or toxicities, and

More from intelligence
Approximately 0 fully matching, plus 13 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....
01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...

Infographics